Lexaria Bioscience (LEXX)
Developer and licensor of DehydraTECH oral drug-delivery technology.
Something off on this page? Send us feedback.
Licenses DehydraTECH, a patent-based oral drug-delivery platform applied to GLP-1 medicines, investigational cannabidiol, nicotine and consumer ingredients. Revenue depends on technology fees, royalties, research support and partner agreements rather than an approved-drug sales base.
Develops and licenses DehydraTECH, a lipid-based formulation and processing platform designed to improve the oral delivery characteristics of active ingredients. Its reusable assets are patents, recipes and know-how rather than manufacturing capacity or a direct sales force.
Applies the platform to GLP-1 medicines, investigational cannabidiol for hypertension, nicotine and selected consumer or bioactive ingredients. Headquarters and central management are in Kelowna, Canada, while the Nevada issuer trades in the United States; patents, studies and vendors span multiple jurisdictions.
Generates prospective economics from license fees, royalties, research support, milestones and pharmaceutical partnerships. Each active ingredient and indication requires its own evidence and, where relevant, regulatory authorization, while growth depends on counterparties converting platform interest into agreements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 26, 2025 | H.C. Wainwright | Target | Target: — | Target: $1.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $3.6M · Total debt $86.7K · Total assets $4.8M · Shareholders' equity $4.7M
- Revenue
- $0
- Operating income
- −$2.0M
- Net income
- −$2.0M
No dividends on record.
| Institutions | 6.62% | 109.4K shares | |
|---|---|---|---|
| 31 holders · as of Jun 30, 2026 | |||
| Insiders | 2.65% | 43.9K shares | |
| 6 holders · as of Mar 18, 2026 | |||
| Other | 90.73% | 1.50M shares | |
| remainder | |||
1.65M company shares as of Sep 9, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Christopher BunkaInsiderdirector | 2.24% | 37,030 | filed Mar 18, 2026 |
Invenomic Capital Management LPInstitution | 1.39% | 345,685 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.20% | 298,436 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.01% | 250,415 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 0.63% | 156,945 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Novo Nordisk (ADR)
Marketed oral semaglutide is the leading GLP-1 delivery benchmark.
- Eli Lilly
Oral and injectable incretins raise the GLP-1 delivery hurdle.
- Rani
Oral robotic capsules rival the platform proposition for biologics.
- Entera Bio
Oral peptide delivery technology targets the same sponsor budgets.
- Aquestive Therapeutics
Oral film formulation competes for drug-delivery development budgets.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lexaria Bioscience | $3.22 | +0.94% | $5.7M | — | — | 29.2 | −88.5% |
| Novo Nordisk (ADR) | $39.42 | +0.03% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Eli Lilly | $1,171.64 | +0.10% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Rani | $0.7999 | +2.83% | $51.6M | — | — | 10.6 | — |
| Entera Bio | $2.98 | −0.17% | $145.9M | — | — | — | — |
| Aquestive Therapeutics | $5.04 | +2.03% | $599.7M | — | — | 11.1 | +38.2% |
| Median | 24.5 | 22.4 | 10.8 | +38.2% |